Spotlighting subgroup analysis, Theravance tries to carve out 'narrow, but critically important' market for failed drug
When Theravance Biopharma revealed last September that its first Phase III trial for ampreloxetine had ended in failure, it demoted the drug from lead status …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
